MHMarijke C. Ph. Slieker-Ten Hove

Marijke C. Ph. Slieker-Ten Hove

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marijke C. Ph. Slieker-Ten Hove has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparing male and female pelvic floor muscle function by the number and type of pelvic floor symptoms

    by Françoise J. M. Notenboom‐Nas, Grietje E. Knol‐De Vries, Marijke C. P. Slieker‐Ten Hove, Janny H. Dekker, Debby G. Keuken, Gommert A. van Koeveringe, Marco H. Blanker

    Aims: Pelvic floor symptoms (PFS), including lower urinary tract symptoms, defecation problems, sexual dysfunction, and pelvic pain, are common in males and females. Comparing pelvic floor musculature (PFM) function between sexes may reveal important differences relevant to clinical care. This study aimed to compare male and female PFM function and to assess the function of both sexes with the number and type of PFS.Methods: We purposively enrolled males and females aged ≥ 21 years with 0–4 PFS based on questionnaire responses in an observational cohort study. Participants then underwent PFM assessment, and muscle function in the external anal sphincter (EAS) and puborectal muscle (PRM) were compared between sexes. The relationships between muscle function and the number and type of PFS were explored.Results: Of the invited 400 males and 608 females, 199 and 187 underwent PFM assessment, respectively. Compared with females, males more often showed increased EAS and PRM tone during assessments. Compared with males, females more often showed weaker maximum voluntary contraction (MVC) of the EAS and dysfunctional endurance of both muscles; additionally, those with zero or one PFS, sexual dysfunction, and pelvic pain more often showed a weak MVC of the PRM.Conclusions: Despite a few similarities between males and, females we found differences in muscle tone, MVC, and endurance between male and female PFM function. These findings provide useful insights into the differences in PFM function between males and females.


  • Open Access

    Exploring concomitant pelvic floor symptoms in community‐dwelling females and males

    by Grietje E. Knol‐De Vries, G. G. Alec Malmberg, Françoise J. M. Notenboom‐Nas, Danny B. H. Voortman, Anouk de Groot, Janny H. Dekker, Gommert A. van Koeveringe, Peter Leusink, Marlies Bosch, Marijke C. Ph. Slieker‐Ten Hove, et al.

    Objectives: Researchers and clinicians tend to focus on one pelvic floor symptom (PFS) at the time. However, the pelvic floor acts as one functional unit, increasing the likelihood of concurrent PFS in patients with pelvic floor dysfunction. There is also a paucity of literature on the prevalence of concomitant PFS, especially in males. Therefore, we explored the occurrence of concomitant PFS in community‐dwelling males and females.Materials and Methods: This prospective observational population‐based cohort study included males and females aged ≥16 years from a single Dutch municipality. Participants completed validated questionnaires on lower urinary tract symptoms (LUTS), defecation problems, sexual dysfunction, pelvic pain, and pelvic organ prolapse. Medical general practitioner records were examined. Furthermore, a randomly selected group of non‐responders aged <80 years received a short questionnaire, to study response bias.Results: We invited 11 724 people, among which 839 females and 566 males completed the questionnaires. Of the female participants, 286 (34.1%) reported no PFS, and 251 (29.9%) reported two or more PFS. The most prevalent PFS clusters in females were sexual dysfunction and pelvic pain, sexual dysfunction and defecation problems, LUTS and defecation problems, and LUTS, defecation problems, and pelvic pain. Of the male participants, 212 (37.5%) reported no PFS, and 191 (33.7%) reported two or more PFS. The most prevalent clusters in males were sexual dysfunction and LUTS, defecation problems and LUTS, and sexual dysfunction, LUTS, and defecation problems.Conclusion: A considerable overlap existed between PFS, with differences in PFS clusters between females and males. Of note, females reported pelvic pain more than males. We conclude that healthcare providers should address all PFS in males and females.


  • Open Access

    Exploring pelvic floor muscle function in men with and without pelvic floor symptoms: A population‐based study

    by Françoise J. M. Notenboom‐Nas, Grietje E. Knol‐De Vries, Lotte Beijer, Yme Tolsma, Marijke C. Ph. Slieker‐Ten Hove, Janny H. Dekker, Gommert A. van Koeveringe, Marco H. Blanker

    Background: Pelvic floor symptoms (PFS), such as lower urinary tract symptoms, defecation disorders, sexual problems, and genital‐pelvic pain, are prevalent in men. Thorough physical assessments of the external anal sphincter (EAS) and the puborectal muscle (PRM) are the keys to unraveling the role of muscle dysfunction.Objectives: To explore associations within and between the EAS and PRM and between muscle (dys‐) function and the number of male PFS.Methods: This cross‐sectional study purposively enrolled men aged ≥21 years with 0–4 symptoms from a larger study. After extensive external and internal digital pelvic floor assessment, we explored (1) agreement between muscle function of the EAS versus PRM (using cross tabulation), (2) associations within and between the EAS and PRM (using heatmaps), and (3) associations between muscle function and number of PFS (using a visual presentation [heatmaps] and χ2 tests).Results: Overall, 42 out of 199 men (21%) had completely normal muscle function. Sixty‐six (33.2%) had no symptoms, of which 53 (80%) had some degree of muscle dysfunction. No clear dose–response relationship existed between muscle (dys‐) function and the number of symptoms. The PRM showed both more dysfunction and severer dysfunction than the EAS.Conclusions: No clear association exists between muscle dysfunction and the number of symptoms, and the absence of PFS does not indicate normal muscle function for all men. Dysfunction levels are highest for the PRM. Further pelvic floor muscle research is warranted in men with PFS.


  • Open Access

    Cost‐effectiveness of an app‐based treatment for urinary incontinence in comparison with care‐as‐usual in Dutch general practice: a pragmatic randomised controlled trial over 12 months

    by Anne M. M. Loohuis, Henk Van Der Worp, Nienke J. Wessels, Janny H. Dekker, Marijke C. Ph. Slieker‐Ten Hove, Marjolein Y. Berger, Karin M. Vermeulen, Marco H. Blanker

    Objective: To assess the cost‐effectiveness of app‐based treatment for female stress, urgency or mixed urinary incontinence (UI) compared with care‐as‐usual in Dutch primary care.Design: A pragmatic, randomised controlled, superiority trial.Setting: Primary care in the Netherlands from 2015 to 2018, follow‐up at 12 months.Population: Women with ≥2 UI‐episodes per week, access to mobile apps, wanting treatment.Methods: The standalone app included conservative management for UI with motivation aids (e.g. reminders). Care‐as‐usual delivered according to the Dutch GP guideline for UI.Main outcome measures: Costs and cost‐effectiveness and ‐utility were assessed from a societal perspective, based on incontinence impact adjusted life years (IIALYs), quality adjusted life years (QALYs) and medical, non‐medical and productivity costs. Information on costs was obtained with the iMCQ and iPCQ questionnaires (medical consumption and productivity cost questionnaires).Results: In all, 262 women were andomised equally to app or care‐as‐usual; 89 (68%) and 83 (63%) attended follow‐up, respectively. Costs were lower for app‐based treatment with € −161 (95% confidence interval [CI −180 to −151) per year. Cost‐effectiveness showed small mean differences in effect for IIALY (0.04) and QALY (−0.03) and thus larger incremental cost‐effectiveness ratios (ICER: −€3696) and incremental cost‐utility ratios (ICUR: €6379).Conclusion: App‐based treatment is a cost‐effective alternative to care‐as‐usual for women with UI in Dutch primary care.Tweetable App‐treatment for female urinary incontinence cost‐effective compared to care‐as‐usual in general practice after 12 months.


  • Open Access

    One year effectiveness of an app‐based treatment for urinary incontinence in comparison to care as usual in Dutch general practice: A pragmatic randomised controlled trial over 12 months

    by Anne M.M. Loohuis, Henk Van Der Worp, Nienke J. Wessels, Janny H. Dekker, Marijke C. Ph. Slieker-Ten Hove, Marjolein Y. Berger, Karin M. Vermeulen, Marco H. Blanker

    Objective: To assess the long‐term effectiveness of app‐based treatment for female stress, urgency or mixed urinary incontinence (UI) compared with care‐as‐usual in primary care.Design: A pragmatic, randomised controlled, superiority trial.Setting: Primary care in the Netherlands from 2015 to 2018, follow up at 12 months.Population: Women with two or more UI episodes per week and access to mobile apps, wanting treatment. A total of 262 women were randomised equally to app or care‐as‐usual; 89 (68%) and 83 (63%) attended 1 year follow up.Interventions: The standalone app included conservative management for UI with motivation aids (e.g. reminders). Care‐as‐usual was delivered according to the Dutch GP guideline for UI.Main outcome measures: Effectiveness assessed by the change in symptom severity score (ICIQ‐UI‐SF) and the change in quality of life (ICIQ‐LUTSqol) with linear regression on an intention‐to‐treat basis.Results: Clinically relevant improvement of UI severity for both app (−2.17 ± 2.81) and care‐as‐usual (−3.43 ± 3.6) groups, with a non‐significant mean difference of 0.903 (−0.66 to 1.871).Conclusion: App‐based treatment is a viable alternative to care‐as‐usual for UI in primary care in terms of effectiveness after 1 year.Tweetable App‐based treatment for female urinary incontinence is a viable alternative to care‐as‐usual after 12 months.


  • Open Access

    The impact of a mobile application‐based treatment for urinary incontinence in adult women: Design of a mixed‐methods randomized controlled trial in a primary care setting

    by Anne M.M. Loohuis, Nienke J. Wessels, Petra Jellema, Karin M. Vermeulen, Marijke C. Slieker‐Ten Hove, Julia E.W.C. van Gemert‐Pijnen, Marjolein Y. Berger, Janny H. Dekker, Marco H. Blanker

    Aims: We aim to assess whether a purpose‐developed mobile application (app) is non‐inferior regarding effectiveness and cost‐effective when used to treat women with urinary incontinence (UI), as compared to care as usual in Dutch primary care. Additionally, we will explore the expectations and experiences of patients and care providers regarding app usage.Methods: A mixed‐methods study will be performed, combining a pragmatic, randomized‐controlled, non‐inferiority trial with an extensive process evaluation. Women aged ≥18 years, suffering from UI ≥ 2 times per week and with access to a smartphone or tablet are eligible to participate. The primary outcome will be the change in UI symptom scores at 4 months after randomization, as assessed by the International Consultation on Incontinence Modular Questionnaire UI Short Form. Secondary outcomes will be the change in UI symptom scores at 12 months, as well as the patient‐reported global impression of improvement, quality of life, change in sexual functioning, UI episodes per day, and costs at 4 and 12 months. In parallel, we will perform an extensive process evaluation to assess the expectations and experiences of patients and care providers regarding app usage, making use of interviews, focus group sessions, and log data analysis.Conclusion: This study will assess both the effectiveness and cost‐effectiveness of app‐based treatment for UI. The combination with the process evaluation, which will be performed in parallel, should also give valuable insights into the contextual factors that influence the effectiveness of such a treatment.